Q1 Earnings Forecast for BPMC Issued By HC Wainwright

Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Blueprint Medicines in a report issued on Thursday, October 31st. HC Wainwright analyst A. Fein forecasts that the biotechnology company will post earnings per share of ($0.60) for the quarter. HC Wainwright has a "Buy" rating and a $135.00 price target on the stock. The consensus estimate for Blueprint Medicines' current full-year earnings is ($3.77) per share. HC Wainwright also issued estimates for Blueprint Medicines' Q2 2025 earnings at ($0.41) EPS and Q3 2025 earnings at ($0.19) EPS.

Other equities research analysts have also recently issued research reports about the stock. Needham & Company LLC restated a "buy" rating and issued a $133.00 price objective on shares of Blueprint Medicines in a research report on Wednesday, October 30th. Barclays upped their price objective on Blueprint Medicines from $75.00 to $105.00 and gave the stock an "equal weight" rating in a report on Monday, July 29th. Baird R W raised Blueprint Medicines to a "strong-buy" rating in a research note on Friday, August 2nd. UBS Group assumed coverage on shares of Blueprint Medicines in a report on Thursday, October 24th. They set a "neutral" rating and a $88.00 target price for the company. Finally, Morgan Stanley boosted their target price on Blueprint Medicines from $110.00 to $115.00 and gave the stock an "equal weight" rating in a research report on Friday, July 12th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $120.39.

Blueprint Medicines Price Performance

Blueprint Medicines stock traded up $1.18 on Monday, reaching $91.88. The company's stock had a trading volume of 580,584 shares, compared to its average volume of 694,166. Blueprint Medicines has a twelve month low of $56.74 and a twelve month high of $121.90. The company has a market cap of $5.84 billion, a price-to-earnings ratio of -43.54 and a beta of 0.59. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.65 and a current ratio of 3.32. The business's fifty day moving average price is $88.79 and its 200 day moving average price is $98.55.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The business had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. During the same period in the previous year, the business earned ($2.20) EPS. The firm's revenue was up 126.5% on a year-over-year basis.

Institutional Trading of Blueprint Medicines

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC bought a new position in Blueprint Medicines during the first quarter worth about $474,000. Hsbc Holdings PLC bought a new stake in Blueprint Medicines in the 2nd quarter valued at $1,060,000. Comerica Bank boosted its position in Blueprint Medicines by 2,582.9% during the first quarter. Comerica Bank now owns 10,839 shares of the biotechnology company's stock worth $1,028,000 after purchasing an additional 10,435 shares during the period. Federated Hermes Inc. increased its holdings in shares of Blueprint Medicines by 27.8% in the second quarter. Federated Hermes Inc. now owns 62,354 shares of the biotechnology company's stock valued at $6,721,000 after purchasing an additional 13,579 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Blueprint Medicines by 82.8% in the second quarter. SG Americas Securities LLC now owns 21,684 shares of the biotechnology company's stock valued at $2,337,000 after purchasing an additional 9,819 shares during the period.

Insiders Place Their Bets

In related news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the sale, the insider now owns 69,070 shares of the company's stock, valued at approximately $6,169,332.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.21% of the company's stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.